Jupiter Diagnostics aims to offer a faster, cheaper way to get blood test results, using a portable and easy-to-use point-of-care diagnostic reader.

Jupiter Diagnostics completed its SyndicateRoom lift round in January 2017 after raising in the region of £1,427,377.

The story

When Jupiter Diagnostics CEO Chris Ball worked as a doctor, he discovered that an urgent blood test usually meant waiting around for hours to get a result - and this was in a busy hospital. While working at Johnson & Johnson, he saw how rapid blood glucose testing could empower patients and accelerate clinical decision-making.

However, no rapid and accurate blood testing was widely available, so he began to look for technology which could deliver high-quality affordable blood testing anywhere. The result is Jupiter Diagnostics.

Jupiter’s development is based on the theory that clinic-based doctors lack ready access to reliable blood tests; currently, they must send the patient, or a blood sample, to a lab and then wait days to receive basic results. With 40 patents granted, Jupiter is looking to build a hospital lab in the palm of your hand, delivering up to eight test results in ten minutes from a single fingerprick of blood at a third of the cost. Jupiter’s diagnostic reader aims to cut out unnecessary time, cost and worry for patients everywhere.

For medical professionals and patients alike, this could reduce paperwork and save time, thereby giving doctors the ability to diagnose and treat patients faster. For national health systems and insurers, this new technology has the potential to lower costs and reduce pressures resulting from waiting times and multiple patient visits. Jupiter has created a works-like/looks-like prototype and has a commercial reader under development.

Jupiter’s difference is that its solution has been developed from the start with the needs of the market in mind. After assessing more than 100 different technologies against these needs, the company has sourced and combined two mature technologies to help create a robust, low-cost and easy-to-use testing hardware solution, and plans to launch its first products in 2017.

The funding from this round will be used to develop additional tests and build sales of its first products.

Video update

The lead investor

Paul Foulger, lead investor for this round, has invested £25,000 into the company.

I am a firm believer in keeping the operational gearing of an early-stage company as low as possible, for as long as possible, and then gearing up as and when milestones are achieved and value is created.

I nearly always invest in companies that I am a director of; I find it hypocritical presenting to potential investors when I have not made a personal commitment myself. I firmly believe in the directors aligning their risk/reward profiles with external investors.

Paul Foulger

Lead investor

Paul is a qualified certified accountant with extensive public and private company experience, having been Finance Director at First Africa Oil plc, Cielo Holdings plc, Elsevier Science, Orogen Gold plc and Porta Communications plc, amongst others.

He jointly led a management buyout of Hansard Group plc in 2004 and managed the buyout of Autoclenz Ltd from the AIM-listed Autoclenz plc in 2012.

Up until December 2015, Paul was CFO at AIM-listed EKF Diagnostics Holdings plc, the global point-of-care medical diagnostics business which has more than 80,000 haemoglobin, A1C, glucose and lactate analysers in regular use in more than 100 countries, running more than 50m tests every year.

Paul is currently CFO at NovaBiotics Ltd, a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases; its current portfolio includes an orphan drug candidate for cystic fibrosis and a potential step change therapy for onychomycosis. He is also a Non-Executive Director for Arcis Biotechnology, a private company focused on providing nucleic acid sample prep solutions, and Autoclenz, the number one service provider to the automative industry.

Paul holds an MBA from Warwick Business School.

See current opportunities

Aeristech Limited

EIS
Engineering & Manufacturing
Aeristech successfully funded twice on SyndicateRoom. They manufacture patented electric superchargers: reducing fuel consumption and CO2 emissions.

Active

Trading status

£9,128

Average investment

£483,766

Total raised

Small Pharma Ltd

EIS
Pharmaceuticals & Biotechnology
Small Pharma is developing an oral rapid-acting antidepressant they believe could make a difference in the lives of those experiencing severe depression.

Active

Trading status

£11,699

Average investment

£783,849

Total raised

Camfridge Limited

EIS
Environment & Renewables
The creator of smart refrigeration technology designed to avoid harmful gases and enable lower cost high-efficiency cooling appliances.

Active

Trading status

£7,935

Average investment

£603,023

Total raised

Showroom Network Limited

EIS
Marketplaces & e-commerce
Showroom allows shoppers to discover and buy products without leaving their favourite blogs and magazine sites. Lead investor Fritz co-founded Doppler Labs and LiveStar. He is an angel investor, investing in more than 60 companies.

Active

Trading status

£8,729

Average investment

£550,534

Total raised

EmbryoCare Limited

EIS
Insurance
EmbryoCare Limited raised funds on SyndicateRoom. Read about the crowdfunding campaign here.

Active

Trading status

£24,297

Average investment

£1,433,500

Total raised

Recycling Technologies - Round 2

EIS
Environment & Renewables
Recycling Technologies offer innovative technology for mixed plastic recycling. The round is led by Damian Tuite who spent 15 years as a currency trader for UBS.

Active

Trading status

£10,714

Average investment

£1,499,999

Total raised